PMN · XBRL financial data

ProMIS Neurosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PMN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,142	2,225*	2,124	1,626	2,564	4,325*	5,464	8,750	9,797	9,368*	6,971	9,522
General and administrative	1,375	1,650*	1,553	1,088	1,871	1,678*	1,996	1,435	1,953	1,404*	1,674	2,745
Total operating expenses	2,518	3,875*	3,677	2,714	4,435	6,002*	7,460	10,185	11,750	10,772*	8,645	12,266
Operating income (loss)	(2,518)	(3,875)*	(3,677)	(2,714)	(4,435)	(6,002)*	(7,460)	(10,185)	(11,750)	(10,772)*	(8,645)	(12,266)
Interest expense	75	—	77	(0)*	0*	—	—	—	—	—	—	—
Other income (expense)	113	188*	132	31	—	year only	112	68	—	year only	401	537
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	—	—	—
Net income (loss)	(2,361)	(3,580)*	(3,635)	(2,624)	9,276	(238)*	(7,348)	(10,117)	(11,580)	(10,674)*	(8,244)	(11,730)
Earnings per share, basic‡ USD per share	(11,875.00)	—	(11,875.00)	(8,125.00)	19,375.00	—	(13,125.00)	(18,125.00)	(15,000.00)	—	(1.26)	(1.28)
Earnings per share, diluted‡ USD per share	(11,875.00)	—	(11,875.00)	(8,125.00)	19,375.00	—	(13,125.00)	(18,125.00)	(15,000.00)	—	(1.26)	(1.28)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	1	1	1	—	6,528	9,142
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	1	1	1	—	6,528	9,142

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (November 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-2500 stock split (November 2025); filings made before it reported them unadjusted.
† Share count changed about 2500x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PMN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	16,868	12,598	2,497	992	21,537	13,291	8,364	4,510	15,399	6,117	63,814	53,429
Short-term investments	32	32	32	32	32	33	33	33	33	34	34	34
Prepaid and other current assets	958	989	1,019	385	2,941	5,587	5,249	4,966	6,026	3,032	1,765	3,231
Total current assets	17,858	13,619	3,548	1,410	24,511	18,911	13,647	9,509	21,458	9,182	65,613	56,694
Total assets	17,876	13,619	3,548	1,410	24,511	18,911	13,647	9,509	21,458	9,182	67,412	56,694
Accounts payable	8,415	7,843	1,404	2,015	1,575	1,737	1,200	2,780	4,211	2,543	1,717	1,793
Accrued liabilities	1,437	1,507	1,242	1,157	1,060	481	2,856	7,044	8,000	7,868	4,898	5,424
Total current liabilities	9,851	9,350	2,646	3,172	2,635	2,218	4,056	9,824	12,211	10,412	6,615	7,218
Total liabilities	11,121	9,866	3,471	3,687	17,237	2,423	4,175	9,892	12,271	10,441	6,694	7,295
Accumulated deficit	(89,886)	(93,466)	(97,101)	(99,725)	(90,449)	(90,687)	(98,035)	(108,152)	(119,732)	(130,406)	(138,651)	(150,380)
Total stockholders' equity	6,755	3,753	77	(2,277)	7,273	16,488	9,472	(383)	9,187	(1,259)	60,718	49,399
Total liabilities and equity	17,876	13,619	3,548	1,410	24,511	18,911	13,647	9,509	21,458	9,182	67,412	56,694
Common shares outstanding (cover page)‡ thousands of shares	0	0	0	0	1	1	1	1	1	4	8,968	8,968

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (November 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-2500 stock split (November 2025); filings made before it reported them unadjusted.
† Share count changed about 2500x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PMN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,361)	(3,580)*	(3,635)	(2,624)	9,276	(238)*	(7,348)	(10,117)	(11,580)	(10,674)*	(8,244)	(11,730)
Stock-based compensation	0*	5*	64	18*	121*	623*	245	212*	197*	203*	189	409*
Net cash from operating activities	(2,376)*	(3,758)*	(10,291)	(1,505)*	(6,671)*	(8,715)*	(4,927)	(3,854)*	(10,056)*	(9,282)*	(12,384)	(10,385)*
Net cash from investing activities	—	year only	—	—	—	year only	—	—	—	year only	—	—
Proceeds from issuing common stock	—	—	190	0*	0*	0*	—	—	—	0*	—	—
Net cash from financing activities	—	(511)*	190	0*	27,216*	470*	—	—	—	(0)*	70,081	0*
Net change in cash	15,646*	(4,270)*	(10,101)	(1,505)*	20,544*	(8,246)*	(4,927)	(3,854)*	10,889*	(9,283)*	57,698	(10,385)*

† Share count changed about 2500x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.